Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial

Scheduled use of CEA and CT follow-up to detect recurrence of colorectal cancer: 6-12 year results from the FACS randomised controlled trial

Bibliografske podrobnosti
Main Authors:	Pugh, SA, Mant, D, Shinkins, B, Mellor, J, Perera, R, Primrose, J
Format:	Conference item
Izdano:	Oxford University Press 2018

Podobne knjige/članki

Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.
od: Primrose, J, et al.
Izdano: (2014)

Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial.
od: Mant, D, et al.
Izdano: (2013)

The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: Results from the FACS trial.
od: Shinkins, B, et al.
Izdano: (2017)

Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial
od: Shinkins, B, et al.
Izdano: (2018)

What is the incidence of resectable recurrence after surgery for primary colorectal cancer? Evidence from the UK FACS (Follow-up After Colorectal Surgery) trial
od: Pugh, S, et al.
Izdano: (2012)

Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postrecurrence survival: data from the FACS randomized controlled trial
od: Pugh, SA, et al.
Izdano: (2016)

Blood CEA levels for detecting recurrent colorectal cancer: A Diagnostic Test Accuracy Review.
od: Nicholson, B, et al.
Izdano: (2015)

Follow up after colorectal surgery (the FACS trial)
od: Corkhill, A, et al.
Izdano: (2004)

WHAT IS THE TRUE INCIDENCE OF METACHRONOUS COLORECTAL LIVER METASTASES? EVIDENCE FROM THE UK FACS (FOLLOW-UP AFTER COLORECTAL SURGERY) TRIAL (ISRCTN: 41458548)
od: Pugh, S, et al.
Izdano: (2012)

CEA monitoring in colorectal cancer is not a waste of time.
od: Mant, D, et al.
Izdano: (2014)

Follow-up after colorectal cancer surgery: Preliminary observational findings from the UK FACS trial
od: Primrose, J, et al.
Izdano: (2011)

A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent
od: Mant, D, et al.
Izdano: (2017)

What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial.
od: Shinkins, B, et al.
Izdano: (2017)

Surveillance for recurrence of colorectal cancer--reply.
od: Primrose, J, et al.
Izdano: (2014)

Carcinoembryonic antigen monitoring to detect recurrence of colorectal cancer: how should we interpret the test results?
od: Shinkins, B, et al.
Izdano: (2014)

Blood measurement of carcinoembryonic antigen level for detecting recurrence of colorectal cancer
od: Nicholson, B, et al.
Izdano: (2016)

CEA-targeted monoclonal antibody therapy in colorectal cancer
od: Conaghan, P, et al.
Izdano: (2009)

PET-CT in oesophageal cancer management: a cost effectiveness analysis (CEA) / Nor Aniza Azmi
od: Azmi, Nor Aniza
Izdano: (2018)

Multivariable prognostic modelling to improve prediction of colorectal cancer recurrence: the PROSPeCT trial
od: Goh, V, et al.
Izdano: (2024)

Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1.
od: Stern, N, et al.
Izdano: (2005)

The Role Of Fdg Pet-Ct In Detection Of Recurrent Colorectal Cancer In National Cancer Institute, Putrajaya, Malaysia
od: Wong, Teck Huat
Izdano: (2016)

Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
od: Nolan, K, et al.
Izdano: (1999)

Performance verification of the MIRI Imager flight model at CEA
od: Ronayette, S, et al.
Izdano: (2010)

Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.
od: Zbar, A, et al.
Izdano: (2005)

Synthesis, DFT studies, and reactions of scandium and yttrium dialkyl cations containing neutral fac-N-3 and fac-S-3 donor ligands
od: Tredget, C, et al.
Izdano: (2008)

A Research Factory for Polymer Microdevices: muFac
od: Hardt, David E., et al.
Izdano: (2010)

Proceedings of the Facs Seminar on priorities in chemistry in developement of Asia.
od: 470714 FACS Seminar on Priorities in Chemistry in Developement of Asia (1981 : Kuala Lumpur)
Izdano: (1981)

Integrated manufacturing execution and control system (FacStream) /
od: 381656 Nazri Abdullah
Izdano: (2001)

Recurrent intussusception in an adult with variable appearances on CT scan and laparotomy findings
od: J., Masiyati, et al.
Izdano: (2015)

QUASAR Collaborative Group: a randomised study of adjuvant chemotherapy (CT) vs observation in predominantly stage II colorectal cancer
od: Kerr, D, et al.
Izdano: (2004)

Optimization of serum free medium for the production of humanized anti-cea monoclonal antibody.
od: Ab Latif, Nurzila
Izdano: (2011)

Optical feedback cavity-enhanced absorption spectroscopy (OF-CEAS) in a ring cavity
od: Hamilton, D, et al.
Izdano: (2010)

Routine follow up of breast cancer in primary care: randomised trial.
od: Grunfeld, E, et al.
Izdano: (1996)

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.
od: Rothwell, P, et al.
Izdano: (2010)

“Johannes fac Totum”?: Shakespeare's first contact with the acting companies
od: Van Es, BB
Izdano: (2010)

Reply: In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
od: Ashraf, S, et al.
Izdano: (2008)

Predicting colorectal cancer risk in patients with rectal bleeding.
od: Robertson, R, et al.
Izdano: (2006)

Automating the tracking of lymph nodes in follow-up studies of thoracic CT images
od: Yu, Peicong, et al.
Izdano: (2013)

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
od: Pace, D, et al.
Izdano: (2015)

Perirectal metachronous recurrence of the hepatocellular carcinoma in the rectum on the 11C choline PET–CT
od: Fathinul Fikri, A.S, et al.
Izdano: (2021)